ArticleOncology letters2019
MicroRNA-342-3p functions as a tumor suppressor by targeting LIM and SH3 protein 1 in oral squamous cell carcinoma.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Identification of a serum-based microRNA signature that detects recurrent oral squamous cell carcinoma before it is clinically evident.British journal of cancer · 2023Article
- Expression profiling of cancer-related long non-coding RNAs revealed upregulation and biomarker potential of HAR1B and JPX in colorectal cancer.Molecular biology reports · 2022Article
- Downregulation of MIAT reduces the proliferation and migratory and invasive abilities of retinoblastoma cells by sponging miR-665 and regulating LASP1.Experimental and therapeutic medicine · 2021Article
- LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression.Bioscience reports · 2020Article
- Article
- miR-342-3p Regulates the Proliferation and Apoptosis of NSCLC Cells by TargetingTechnology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although microRNA-342-3p (miR-342-3p) deregulation has been implicated in the development of a variety of cancer types, its role in oral squamous cell carcinoma (OSCC) progression remains unclear. Overexpression of LIM and SH3 protein 1 (LASP1) in OSCC tissues, and its promotion of OSCC cell proliferation were recently reported. However, the regulatory mechanism underlining LASP1 expression remains unknown. In the present study, the notable downregulation of miR-342-3p in OSCC cell lines and clinical specimens was revealed. The Cell Counting kit-8 and 5-bromo-2-deoxyuridine-incorporation assays demonstrated that miR-342-3p suppressed OSCC cell proliferation. Additionally, LASP1 was identified as a target gene of miR-342-3p through bioinformatics analysis and luciferase reporter assays. Further experiments suggested that overexpression of LASP1 attenuated the suppressive effect of miR-342-3p on the proliferation of OSCC cells. In conclusion, the present data suggest that miR-342-3p functions as a tumor suppressor in OSCC via targeting of LASP1 and may be a promising therapeutic target for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.